Inhibikase Therapeutics (IKT) Net Income towards Common Stockholders Growth (3y) (2023 - 2026)
Inhibikase Therapeutics (IKT) Net Income towards Common Stockholders Growth (3y) (2023 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Net Income Growth (3y) (Qtr) |
| 1 |
Alterity Therapeutics |
762,369.55 Bn |
762,369.51 Bn |
- |
- |
| 2 |
Belite Bio |
55,096.00 Bn |
55,096.00 Bn |
- |
84.25% |
| 3 |
Quantum Biopharma |
17,755.80 Bn |
17,755.79 Bn |
- |
-10.84% |
| 4 |
Legend Biotech |
3,486.00 Bn |
3,485.71 Bn |
242.10 Mn |
26.38% |
| 5 |
Akari Therapeutics |
1,737.42 Bn |
1,737.41 Bn |
- |
-46.86% |
| 6 |
Evaxion A |
1,551.28 Bn |
1,551.26 Bn |
- |
34.98% |
| 7 |
Psyence Biomedical |
227.32 Bn |
227.31 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
110.84 Bn |
103.59 Bn |
2.59 Bn |
13.80% |
| 9 |
Abivax |
91.71 Bn |
91.71 Bn |
- |
- |
| 10 |
Inhibikase Therapeutics |
285.17 Mn |
114.80 Mn |
- |
-55.83% |
| Date | Value |
|---|
| Mar 31, 2026 |
-55.83% |
| Dec 31, 2025 |
-47.02% |
| Sep 30, 2025 |
-41.63% |
| Jun 30, 2025 |
-32.66% |
| Mar 31, 2025 |
-46.52% |
| Dec 31, 2024 |
-36.88% |
| Sep 30, 2024 |
-9.23% |
| Jun 30, 2024 |
-24.20% |
| Mar 31, 2024 |
-21.95% |
| Dec 31, 2023 |
-53.90% |
| Sep 30, 2023 |
-92.30% |
| Jun 30, 2023 |
-144.98% |
| Mar 31, 2023 |
-104.98% |
